Tekturna
(Aliskiren)ApprovedSmall molecule
Tibotec Pharmaceuticals, IrelandAliskiren is used to treat high blood pressure. It helps relax blood vessels so blood can flow more easily, which lowers your blood pressure and reduces strain on your heart.[2] Tekturna is currently approved and in use across 24 indications[4].[1]
Tekturna is one of 457 small molecule programs targeting Metabolic Syndrome. It is currently in Approved.
24
Indications
131
Total Trials
1
Active Trials
456
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
2
Patents
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 24 indications
Competition
Competitive Landscape
206 competitors in Heart Failure
#DrugCompanyPhaseTrials
1Tekturna
Tibotec Pharmaceuticals, IrelandApproved
Bayer Aspirin
BayerPreclinical
Brethine
SanofiPreclinical
Medrol
PfizerPreclinical
Amidate
PfizerPreclinical
Activase
RochePreclinical
Zemplar
AbbViePreclinical
Adriamycin
PfizerPreclinical
Savaysa
Daiichi SankyoPreclinical
Xifaxan
SSalix
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Hypertension22 trials
Show 19 more trials
Effect of Aliskiren and Hydrochlorothiazide on Kidney Oxygenation in Patients With Hypertension
Completed·—·Phase 4·NCT01519635·24 enrolled
Essential Hypertension10 trials
Show 7 more trials
Hypertensive9 trials
Show 6 more trials
Heart Failure8 trials
Show 5 more trials
High Blood Pressure6 trials
Show 3 more trials
50 more indications
Safety and Efficacy6 trials
Show 3 more trials
Efficacy and Safety4 trials
Type 2 Diabetes4 trials
Diabetes Mellitus3 trials
Aliskiren's Effect on Arterial Stiffness and Platelet Function in Patients With Diabetes Mellitus (DM)
Unknown status·—·N/A·NCT00732407·40 enrolled
Blood Pressure3 trials
Endothelial Function3 trials
The Effect of Aliskiren on Endothelial Function in Pre-Diabetes and Diabetes
Completed·—·N/A·NCT01165983·124 enrolled
Metabolic Syndrome3 trials
Albuminuria2 trials
Left Ventricular Hypertrophy2 trials
Chronic Kidney Disease2 trials
Kidney Transplant2 trials
Effect of Short Term Aliskiren Treatment in Kidney Transplant Patients
Terminated·—·Phase 4·NCT01437943·10 enrolled
Biomarkers2 trials
End-Stage Renal Disease1 trial
Combination Therapy1 trial
Drug1 trial
Atrial Fibrillation1 trial
Coronary Artery Disease1 trial
Kidney Disease1 trial
Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease
Terminated·—·Phase 4·NCT01129557·46 enrolled
Hyperuricemia1 trial
Non-Inferiority Study of Aliskiren vs Losartan in the Treatment of Hypertension With Hyperuricemia
Completed·—·Phase 4·NCT06718062·66 enrolled
Systolic Heart Failure1 trial
ALD1 trial
Atherosclerosis1 trial
Acute Coronary Syndrome1 trial
Nephropathy1 trial
Aliskiren for Immunoglobulin A (IgA) Nephropathy
Completed·—·Phase 3·NCT00870493·22 enrolled
C3 Glomerulopathy1 trial
Diabetic Nephropathy1 trial
Cardiac Transplant1 trial
Type 2 Diabetes Mellitus1 trial
Peritoneal Dialysis1 trial
The Effect of Aliskiren and Losartan on Peritoneal Membrane in Continuous Ambulatory Peritoneal Dialysis Patients
Unknown status·—·Phase 4·NCT01305850·100 enrolled
Insulin Sensitivity1 trial
Assessment of Renin Inhibition on Insulin Sensitivity, Diastolic Function and Aortic Compliance
Terminated·—·N/A·NCT01252238·24 enrolled
IgA Nephropathy1 trial
Endothelial Dysfunction1 trial
Medication1 trial
Randomized Controlled Trial1 trial
Myocardial Infarction1 trial
Hemodynamic1 trial
Congestive Heart Failure1 trial
Regulatory
FDA Approval Timeline[5]
Mar 5, 2007
TEKTURNA
NDA NDA021985
Nov 14, 2017
TEKTURNA
NDA NDA210709
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Tekturna drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Aliskiren. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]